These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ; Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314 [TBL] [Abstract][Full Text] [Related]
3. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594 [TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors. Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418 [TBL] [Abstract][Full Text] [Related]
5. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice. Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493 [TBL] [Abstract][Full Text] [Related]
7. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111 [TBL] [Abstract][Full Text] [Related]
9. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Naftali T; Bar-Lev Schleider L; Dotan I; Lansky EP; Sklerovsky Benjaminov F; Konikoff FM Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1276-1280.e1. PubMed ID: 23648372 [TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668 [TBL] [Abstract][Full Text] [Related]
11. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375 [TBL] [Abstract][Full Text] [Related]
12. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954 [TBL] [Abstract][Full Text] [Related]
13. Implementing changes in clinical practice to improve the management of Crohn's disease. Panaccione R; Hibi T; Peyrin-Biroulet L; Schreiber S J Crohns Colitis; 2012 Feb; 6 Suppl 2():S235-42. PubMed ID: 22463930 [TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease. Tang DH; Armstrong EP; Lee JK Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603 [TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy with certolizumab pegol for Crohn's disease. Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ; N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459 [TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Mansfield JC; Parkes M; Hawthorne AB; Forbes A; Probert CS; Perowne RC; Cooper A; Zeldis JB; Manning DC; Hawkey CJ Aliment Pharmacol Ther; 2007 Aug; 26(3):421-30. PubMed ID: 17635377 [TBL] [Abstract][Full Text] [Related]
17. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
18. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Panés J; López-Sanromán A; Bermejo F; García-Sánchez V; Esteve M; Torres Y; Domènech E; Piqueras M; Gomez-García M; Gutiérrez A; Taxonera C; Sans M; Gastroenterology; 2013 Oct; 145(4):766-74.e1. PubMed ID: 23770132 [TBL] [Abstract][Full Text] [Related]
19. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease. Smith LS; Nelson M; Dolder CR Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143 [TBL] [Abstract][Full Text] [Related]